1
|
Lins LAB, Birch CM, Berde C, Emans J, Hedequist D, Hresko MT, Karlin L, Glotzbecker MP. Late-presenting dural leak following spine fusion in the pediatric population. Spine Deform 2023; 11:1371-1380. [PMID: 37488330 DOI: 10.1007/s43390-023-00720-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2022] [Accepted: 06/10/2023] [Indexed: 07/26/2023]
Abstract
PURPOSE The purpose is to describe how patients with a late-presenting dural leak (LPDL) after posterior spinal fusion (PSF) was diagnosed and treated at a single institution. METHODS Of the 1991 patients who underwent a PSF between 2010 and 2018, 6 patients were identified with a clinical course consistent with a potential LPDL. RESULTS Six patients with median age 16.9 years had onset of headache ranging 1-12 weeks postoperatively (median 6.5 weeks). All six patients presented with positional headache, and half (3/6) presented with emesis. 5/6 patients underwent contrast brain MRI, which demonstrated pachymeningeal enhancement. 4/5 patients with dural enhancement went on to have CT myelogram. Five patients had a CT myelogram, which identified a dural leak in all patients and localized the leak in four of five patients. All patients underwent an epidural blood patch, which resolved the pain in five patients. One patient without relief underwent revision surgery with removal of a medially placed screw and fibrin glue placement resolving symptoms. CONCLUSIONS Postoperative dural leaks associated with PSF may present in a delayed fashion. The majority of leaks were not associated with screw malposition. In diagnosing patients with suspected LPDL, we suggest brain MRI with contrast as a first step. Most patients with pachymeningeal enhancement shown on contrast brain MRI had dural leaks that were identified through CT myelograms. For patients with a dural leak, if there is no disruption from screws, a blood patch appears to be an effective treatment. LEVEL OF EVIDENCE IV.
Collapse
Affiliation(s)
- Laura A B Lins
- Department of Orthopedics and Rehabilitation, University of Wisconsin Hospitals and Clinics, Madison, WI, USA.
| | - Craig M Birch
- Department of Orthopedics, Boston Children's Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - Charles Berde
- Harvard Medical School, Boston, MA, USA
- Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA, USA
| | - John Emans
- Department of Orthopedics, Boston Children's Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - Daniel Hedequist
- Department of Orthopedics, Boston Children's Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - M Timothy Hresko
- Department of Orthopedics, Boston Children's Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - Lawrence Karlin
- Department of Orthopedics, Boston Children's Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - Michael P Glotzbecker
- Department of Orthopedics, Boston Children's Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
- Department of Orthopedics, Rainbow Babies and Children's Hospital, Cleveland, OH, USA
| |
Collapse
|
2
|
Macro M, Hulin C, Vincent L, Charvet-Rumpler A, Benboubker L, Calmettes C, Stoppa AM, Laribi K, Clement-Filliatre L, Zerazhi H, Honeyman F, Richez V, Maloisel F, Karlin L, Barrak J, Chouaid C, Leleu X. Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study. Ann Hematol 2023:10.1007/s00277-023-05278-3. [PMID: 37301786 DOI: 10.1007/s00277-023-05278-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2023] [Accepted: 05/15/2023] [Indexed: 06/12/2023]
Abstract
Ixazomib (IXA) is an oral proteasome inhibitor (PI) used in combination with lenalidomide and dexamethasone (IXA-Rd) for patients with relapsed and/or refractory multiple myeloma (RRMM). The REMIX study is one of the largest prospective, real-world analysis of the effectiveness of IXA-Rd in the setting of RRMM. Conducted in France between August 2017 and October 2019, the REMIX study, a non-interventional prospective study, included 376 patients receiving IXA-Rd in second line or later and followed for at least 24 months. Primary endpoint was the median progression-free survival (mPFS). Median age was 71 years (Q1-Q3 65.0 - 77.5) with 18.4% of participants older than 80 years. IXA-Rd was initiated in L2, L3 and L4 + for 60.4%, 18.1% and 21.5%, respectively. mPFS was 19.1 months (95% CI [15.9, 21.5]) and overall response rate (ORR) was 73.1%. mPFS was 21.5, 21.9 and 5.8 months in patients receiving IXA-Rd as L2, L3, L4 + respectively. Among patients receiving IXA-Rd in L2 and L3, mPFS was similar for patients previously exposed to lenalidomide (19.5 months) than for those lenalidomide naive (not exposed, 22.6 months, p = 0.29). mPFS was 19.1 months in patients younger than 80 years and 17.4 months in those 80 years or older (p = 0.06) with similar ORR (72.4% and 76.8%) in both subgroups. Adverse events (AEs) were reported in 78.2% of patients including 40.7% of treatment-related AE. IXA discontinuation was due to toxicity in 21% of patients. To conclude, the results of the REMIX study are consistent with the results of Tourmaline-MM1 and confirm the benefit of IXA-Rd combination in real life. It shows the interest of IXA-Rd in an older and frailer population, with an acceptable effectiveness and tolerance.
Collapse
Affiliation(s)
- M Macro
- IHBN - CHU de Caen, Caen, France.
| | - C Hulin
- CHU Bordeaux - Hôpital Haut Leveque, Pessac, France
| | - L Vincent
- CHU de Montpellier - Hôpital Saint-Eloi, Montpellier, France
| | | | - L Benboubker
- CHRU de Tours - Hôpital Bretonneau, Tours, France
| | | | - A-M Stoppa
- Institut Paoli Calmettes, Marseille, France
| | | | | | | | - F Honeyman
- CHU de Saint-Etienne, Saint-Etienne, France
| | - V Richez
- CHU de Nice - Hôpital de l'archet, Nice, France
| | - F Maloisel
- Clinique Sainte-Anne, Strasbourg, France
| | - L Karlin
- Hospices Civils de Lyon, Pierre Bénite, France
| | | | | | - X Leleu
- CHU de Poitiers, Poitiers, France
| |
Collapse
|
3
|
O'Neill N, Ghessese S, Hedequist D, Lins L, Birch C, Hresko MT, Emans J, Karlin L, Cornelissen L, Glotzbecker M. Quantitative Sensory Changes Following Posterior Spinal Fusion to Treat Adolescent Idiopathic Scoliosis. J Pediatr Orthop 2023; 43:218-226. [PMID: 36737054 DOI: 10.1097/bpo.0000000000002362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND Sensory changes surrounding the incision frequently develop after posterior spinal fusion (PSF) to treat adolescent idiopathic scoliosis (AIS). Anecdotally, patients may experience sensory changes on the chest wall. Such postsurgical sensory changes are not well described quantitatively. This study aims to evaluate the presence, intensity, and duration of mechanical sensory changes in AIS patients postoperatively. METHODS A prospective cohort of AIS patients, 10 to 21 years old, was followed. Quantitative sensory testing (QST) included touch detection threshold [mechanical detection threshold (MDT)] and pain detection threshold (MPT), using VonFrey monofilaments and pinprick stimulators. QST was performed at 3 sites at T6: the right and left chest at the nipple line and adjacent to the incision below the inferior angle of the scapula. QST at the thenar eminence was the control. QST was collected at baseline, 3 days, 1, and 6 months postoperative. RESULTS Thirty-four patients (21% males; mean age: 14.9 years old; median preoperative curve: 58 degrees) completed all testing. Mean deformity correction was 64% (SD: 10.4). Adjacent to the incision site, MDT was significantly higher compared with baseline at 3 days and 1 month ( P < 0.001) but not at 6 months ( P = 0.19), whereas MPT was significantly higher at 3 days, ( P < 0.001), 1 month ( P < 0.001), and 6 months ( P = 0.001). For the chest wall in all patients, MPT was higher on the left chest at 3 days ( P = 0.04) and on the right chest at 3 days ( P = 0.022) and 1 month ( P = 0.05). For patients with right-sided curves, MDT ( P = 0.01) and MPT ( P = 0.015) overall were significantly higher on the concave side (left) chest postoperatively. CONCLUSIONS PSF is associated with sensory disturbances that are detectable within days, persist at 1 month, and improve at 6 months postoperatively adjacent to the incision and on the chest wall. We suspect that these sensory changes are transient. Describing postoperative sensory changes will help us better set postoperative expectations for patients undergoing PSF. LEVEL OF EVIDENCE Level I.
Collapse
Affiliation(s)
- Nora O'Neill
- Boston Children's Hospital, Harvard Medical School, Boston, MA
| | - Semhal Ghessese
- Boston Children's Hospital, Harvard Medical School, Boston, MA
| | | | - Laura Lins
- Boston Children's Hospital, Harvard Medical School, Boston, MA
| | - Craig Birch
- Boston Children's Hospital, Harvard Medical School, Boston, MA
| | | | - John Emans
- Boston Children's Hospital, Harvard Medical School, Boston, MA
| | - Lawrence Karlin
- Boston Children's Hospital, Harvard Medical School, Boston, MA
| | | | - Michael Glotzbecker
- Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH
| |
Collapse
|
4
|
Magee L, Bram JT, Anari JB, Ramo B, Mayer OH, Matsumoto H, Brooks JT, Andras L, Lark R, Fitzgerald R, Truong W, Li Y, Karlin L, Schwend R, Weinstein S, Roye D, Snyder B, Flynn JM, Oetgen M, Smith J, Cahill PJ. Outcomes and Complications in Management of Congenital Myopathy Early-Onset Scoliosis. J Pediatr Orthop 2021; 41:531-536. [PMID: 34325442 DOI: 10.1097/bpo.0000000000001922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND Congenital myopathies (CMs) are complex conditions often associated with early-onset scoliosis (EOS). The purpose of this study was to investigate radiographic outcomes in CM patients undergoing EOS instrumentation as well as complications. Secondarily, we sought to compare these patients to a population with higher prevalence, cerebral palsy (CP) EOS patients. METHODS This is a retrospective study of a prospectively collected multicenter registry. The registry was queried for EOS patients with growth-sparing instrumentation (vertical expandable prosthetic titanium ribs, magnetically controlled growing rods, traditional growing rod, or Shilla) and a CM or CP diagnosis with minimum 2 years follow-up. Outcomes included major curve magnitude, T1-S1 height, kyphosis, and complications. RESULTS Sixteen patients with CM were included. Six (37.5%) children with CM experienced 11 complications by 2 years. Mean major curve magnitude for CM patients was improved postoperatively and maintained at 2 years (P<0.01), with no significant increase in T1-S1 height or maximum kyphosis(P>0.05). Ninety-seven patients with CP EOS were included as a comparative cohort. Fewer CP patients required baseline respiratory support compared with CM patients (20.0% vs. 92.9%, P<0.01). Fifty-four (55.7%) CP patients experienced a total of 105 complications at 2 years. There was no evidence that the risk of complication or radiographic outcomes differs between cohorts at 2 years, though CP EOS patients experienced significant improvement in all measurements at 2 years. CONCLUSIONS EOS CM children face a high risk of complication after growing instrumentation, with similar curve correction and risk of complication to CP patients. LEVEL OF EVIDENCE Level III.
Collapse
Affiliation(s)
- Lacey Magee
- Children's Hospital of Philadelphia, Division of Orthopaedics
| | - Joshua T Bram
- Children's Hospital of Philadelphia, Division of Orthopaedics
| | - Jason B Anari
- Children's Hospital of Philadelphia, Division of Orthopaedics
| | - Brandon Ramo
- Texas Scottish Rite Hospital for Children, Dallas, TX
| | - Oscar H Mayer
- Children's Hospital of Philadelphia, Division of Pulmonary Medicine, Philadelphia, PA
| | - Hiroko Matsumoto
- Columbia University Medical Center, Division of Pediatric Orthopedics, New York, NY
| | | | | | - Robert Lark
- Department of Orthopaedics, Duke University, Durham, NC
| | | | - Walter Truong
- Gillette Children's Specialty Healthcare, St. Paul, MN
| | - Ying Li
- C.S. Mott Children's Hospital, Ann Arbor, MI
| | | | | | | | - David Roye
- Columbia University Medical Center, Division of Pediatric Orthopedics, New York, NY
| | | | - John M Flynn
- Children's Hospital of Philadelphia, Division of Orthopaedics
| | | | - John Smith
- Primary Children's Medical Center, University of Utah, Salt Lake City, UT
| | | |
Collapse
|
5
|
Hogue G, DeWitt L, Grzywna A, Hresko MT, Hedequist D, Karlin L, Emans J, Le H, Miller P, Glotzbecker M. Does bracing for adolescent idiopathic scoliosis affect operative results? Spine Deform 2020; 8:427-432. [PMID: 32291582 DOI: 10.1007/s43390-020-00066-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Accepted: 12/21/2019] [Indexed: 11/26/2022]
Abstract
STUDY DESIGN Retrospective comparative study. OBJECTIVES We hypothesize that preoperative bracing for idiopathic scoliosis results in increased stiffness, as measured by reduced correction on bending films, ultimately leading to decreased surgical correction. Bracing is the primary nonoperative treatment for immature AIS patients with mild to moderate curves. For patients who fail bracing and proceed to operative intervention, it is unknown whether their nonoperative treatment impacts their surgical results. METHODS We conducted a single-center, retrospective, comparative study on 181 consecutive adolescent idiopathic scoliosis patients, aged 11-17 years, who underwent posterior spine fusion between 2011 and 2013. Patient flexibility was measured as percent change in the curve angle of the spine from standing to supine bend. Overall curve correction was calculated as the preoperative to postoperative change in standing coronal measure divided by the preoperative measurement and reported as a percentage. RESULTS One hundred and twelve subjects (62%) underwent bracing prior to fusion. Braced patients had similar preoperative major Cobb angles than unbraced patients (56.5 vs 59.0, p = 0.07). Preoperatively, braced patients achieved less primary curve correction in bending films (33.6%) than unbraced patients (40.6%, p = 0.003). Postoperatively, Cobb angle correction was not different between the braced (75.7%) and unbraced group (77.2%) overall (p = 0.41). There was no difference in blood loss (p = 0.14) or surgical time (p = 0.96) between braced and unbraced groups when adjusted for surgeon and number of levels fused. CONCLUSIONS While braced patients may demonstrate less preoperative flexibility, there is no evidence that braced patients experience decreased curve correction compared to unbraced patients. Bracing treatment did not impact operative results, as indicated by similar Cobb angle correction, estimated blood loss, and surgical time in both groups. LEVEL OF EVIDENCE III.
Collapse
Affiliation(s)
- Grant Hogue
- Department of Orthopaedics, Children's Health at University Hospital, San Antonio, TX, USA
| | - Leah DeWitt
- Department of Orthopaedic Surgery, Boston Children's Hospital, Boston, MA, USA
| | - Alexandra Grzywna
- Department of Orthopaedic Surgery, Boston Children's Hospital, Boston, MA, USA
| | - M Timothy Hresko
- Department of Orthopaedic Surgery, Boston Children's Hospital, Boston, MA, USA
| | - Daniel Hedequist
- Department of Orthopaedic Surgery, Boston Children's Hospital, Boston, MA, USA
| | - Lawrence Karlin
- Department of Orthopaedic Surgery, Boston Children's Hospital, Boston, MA, USA
| | - John Emans
- Department of Orthopaedic Surgery, Boston Children's Hospital, Boston, MA, USA
| | - Hai Le
- Department of Orthopaedic Surgery, Boston Children's Hospital, Boston, MA, USA
| | - Patricia Miller
- Department of Orthopaedic Surgery, Boston Children's Hospital, Boston, MA, USA
| | - Michael Glotzbecker
- Department of Orthopaedic Surgery, Boston Children's Hospital, Boston, MA, USA.
| |
Collapse
|
6
|
Wang M, Ramchandren R, Chen R, Karlin L, Chong G, Jurczak W, Wu K, Bishton M, Collins G, Eliadis P, Peyrade F, Freise K, Sukbuntherng J, Lee Y, Dobkowska E, Fedorov V, Neuenburg J, Tam C. RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE SYMPATICO STUDY EVALUATING IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.146_2630] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Wang
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston United States
| | - R. Ramchandren
- Department of Oncology; Karmanos Cancer Institute; Detroit United States
| | - R. Chen
- Department of Hematology & Hematopoietic Cell Transplantation; City of Hope; Duarte United States
| | - L. Karlin
- Department of Hematology; Centre Hospitalier Lyon Sud; Pierre-Bénite France
| | - G. Chong
- Department of Medical Oncology and Clinical Haematology; Olivia Newton-John Cancer Centre, and University of Melbourne; Melbourne Australia
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Kraków Poland
| | - K. Wu
- Department of Hematology; Ziekenhuis Netwerk Antwerpen; Antwerp Belgium
| | - M. Bishton
- Department of Clinical Haematology; Nottingham University Hospitals NHS Trust; Nottingham United Kingdom
| | - G. Collins
- Department of Hematology; Oxford University Hospitals, NHS Foundation Trust; Oxford United Kingdom
| | - P. Eliadis
- Department of Oncology; ICON Cancer Care; South Brisbane Australia
| | - F. Peyrade
- Department of Oncology; Centre Antoine Lacassagne; Nice France
| | - K. Freise
- Department of Clinical Pharmacology and Pharmacometrics; AbbVie Inc; North Chicago United States
| | - J. Sukbuntherng
- Department of Drug Metabolism & Pharmacokinetics; Pharmacyclics LLC, an AbbVie Company; Sunnyvale United States
| | - Y. Lee
- Department of Biostatistics; Pharmacyclics LLC, an AbbVie Company; Sunnyvale United States
| | - E. Dobkowska
- Department of Clinical Science; Pharmacyclics LLC, an AbbVie Company; Sunnyvale United States
| | - V. Fedorov
- Department of Clinical Science; Pharmacyclics LLC, an AbbVie Company; Sunnyvale United States
| | - J. Neuenburg
- Department of Clinical Science; Pharmacyclics LLC, an AbbVie Company; Sunnyvale United States
| | - C. Tam
- Department of Haematology; Peter MacCallum Cancer Centre & St. Vincent's Hospital and the University of Melbourne; Melbourne Australia
| |
Collapse
|
7
|
Grzywna A, McClung A, Sanders J, Sturm P, Karlin L, Glotzbecker M, Children’s Spine Study Group, Growing Spine Study Group. Survey to describe variability in early onset scoliosis cast practices. J Child Orthop 2018; 12:406-412. [PMID: 30154933 PMCID: PMC6090186 DOI: 10.1302/1863-2548.12.170207] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
PURPOSE To investigate paediatric orthopaedists' cast practices for early onset scoliosis regarding patient selection, cast application, radiographic evaluation, treatment cessation and adjunctive bracing. METHODS A casting survey was distributed to all paediatric orthopaedists in Children's Spine and Growing Spine Study Groups (n = 92). Questions included physician and patient characteristics, technique, treatment, outcomes, radiographic measurements and comparison to other treatments. A total of 55 orthopaedists (60%) responded, and descriptive statistics were calculated on the subset who cast (n = 45). RESULTS A majority of respondents use cast treatment for idiopathic and syndromic scoliosis patients, but not for neuromuscular or congenital scoliosis patients. Major curve angle ranked most important in orthopaedists' decision to commence cast treatment, in comparison with rib-vertebra angle difference or clinical observations. The major curve angle threshold to initiate casting was a median of 30° (20° to 70°), and the minimum patient age was median ten months (3 to 24). First in-cast and out-of-cast radiographs are taken standing, supine, awake, under anesthesia and/or in traction. In all, 58% consistently cast over or under the arm, while 44% vary position by patient. Respondents were divided about the use of a brace after cast treatment: 22% do not prescribe a brace, 31% always do and 36% do in some patients. CONCLUSIONS Future multicentre research studies must standardize radiographic practices and consider age and major curve angle at cast initiation and termination, scoliosis aetiology, shoulder position and treatment duration. Practices need to be aligned or compared in these areas in order to distinguish what makes for the best cast treatment possible.Level of Evidence: V, Expert opinion.
Collapse
Affiliation(s)
- A. Grzywna
- Department of Orthopedic Surgery, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - A. McClung
- Growing Spine Foundation, Milwaukee, Wisconsin, USA
| | - J. Sanders
- Department of Orthopaedics, University of Rochester Medical Center, Rochester, New York, USA
| | - P. Sturm
- Department of Orthopedic Surgery, Cinncinnati Children’s Hospital, Cinncinnati, Ohio, USA
| | - L. Karlin
- Department of Orthopedic Surgery, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - M. Glotzbecker
- Department of Orthopedic Surgery, Boston Children’s Hospital, Boston, Massachusetts, USA, Correspondence should be sent to M. Glotzbecker, 300 Longwood Avenue, Hunnewell 2, Boston, Massachussetts 02115, United States. E-mail:
| | | | | |
Collapse
|
8
|
|
9
|
Gressin R, Daguindau N, Tempescul A, Moreau A, Carras S, Cartron G, Schmitt A, Houot R, Dartigeas C, Pignon J, Corm S, Bannos A, Mounier C, Dupuis J, Macro M, Fleury J, Jardin F, Karlin L, Damaj G, Feugier P, Fornecker L, Chabrot C, Ysebaert I, Callanan M, Le Gouill S. FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_131] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- R. Gressin
- Onco-Hematology; University Hospital; Grenoble France
| | | | | | - A. Moreau
- Pathology; University Hospital; Nantes France
| | - S. Carras
- Onco-Hematology; University Hospital; Grenoble France
| | - G. Cartron
- Hematology; Hospital University; Montpellier France
| | - A. Schmitt
- Hematology; Caner Center; Bordeaux France
| | - R. Houot
- Hematology; University Hospital; Rennes France
| | | | - J. Pignon
- Hematology, Hospital; Dunkerque France
| | - S. Corm
- Hematology, Hospital; Chambery France
| | - A. Bannos
- Hematology, Hospital; Bayonne France
| | - C. Mounier
- Hematology; Cancer Institute, St Priest en Jares; France
| | - J. Dupuis
- Hematology; University Hospital; Creteil France
| | - M. Macro
- Hematology; University Hospital; Caen France
| | - J. Fleury
- Hematology, Clinic; Clermont Ferrand France
| | - F. Jardin
- Hematology; Cancer Institute; Rouen France
| | - L. Karlin
- Hematology; University Hospital; France
| | - G. Damaj
- Hematology; University Hospital; Amiens France
| | - P. Feugier
- Hematology; University Hospital, Vandoeuvre Les Nancy; France
| | - L. Fornecker
- Hematology; University Hospital; Strasbourg France
| | - C. Chabrot
- Hematology; University Hospital; Clermont Ferrand France
| | - I. Ysebaert
- Hematology; University Hospital; Toulouse France
| | - M. Callanan
- INSERM U1209; Institute For Advanced Biosciences; La Tronche France
| | | |
Collapse
|
10
|
Bonnet C, Lamy T, Fruchart C, Legouill S, Gunzer K, Gastinne T, Jardin F, Karlin L, Houot R, Dupuis J, Tilly H, Salles G. IBRUTINIB IN ASSOCIATION WITH R-DHAP/OX FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA: PRELIMINARY RESULTS OF THE BIBLOS PHASE IB LYSA STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- C.M. Bonnet
- Clinical Hematology, Chu Liege; Angleur Belgium
| | - T. Lamy
- Hematology, Chu Rennes; Rennes France
| | - C. Fruchart
- Hematology; Centre François Baclesse Caen; Caen France
| | - S. Legouill
- Hematology, C.H.U. - Hotel Dieu; Nantes France
| | - K. Gunzer
- Hematology; Centre François Baclesse Caen; Caen France
| | - T. Gastinne
- Hematology, C.H.U. - Hotel Dieu; Nantes France
| | - F. Jardin
- Hematology; Centre Henri Becquerel; Rouen France
| | - L. Karlin
- Hematology; Centre Hospitalier Lyon-Sud, Pierre Benite; France
| | - R. Houot
- Hematology, Chu Rennes; Rennes France
| | - J. Dupuis
- Hematology; HU Henri Mondor Aphp, Creteil, Val-De-Marne; France
| | - H. Tilly
- Hematology; Centre Henri Becquerel; Rouen France
| | - G. Salles
- Hematology; Centre Hospitalier Lyon-Sud, Pierre Benite; France
| |
Collapse
|
11
|
Fouquet G, Pegourie B, Macro M, Petillon MO, Karlin L, Caillot D, Roussel M, Arnulf B, Mathiot C, Marit G, Kolb B, Stoppa AM, Brechiniac S, Richez V, Rodon P, Banos A, Wetterwald M, Garderet L, Royer B, Hulin C, Benbouker L, Decaux O, Escoffre-Barbe M, Fermand JP, Attal M, Avet-Loiseau H, Moreau P, Facon T, Leleu X. Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma. Ann Oncol 2016; 27:902-7. [PMID: 26787238 DOI: 10.1093/annonc/mdw017] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Accepted: 01/07/2016] [Indexed: 01/20/2023] Open
Abstract
BACKGROUND The IFM2009-02 trial studied pomalidomide (4 mg daily, 21/28 versus 28/28) and dexamethasone in very advanced relapsed or refractory multiple myeloma (RRMM). We observed that 40% of patients had a prolonged progression-free survival (PFS) and subsequently overall survival (OS). We sought to analyze the characteristics of these patients and study the effect of long exposure to pomalidomide. DESIGN We separated the studied population into two groups: 3 months to 1 year (<1 year) and more than 1 year (≥1 year) of treatment with pomalidomide and dexamethasone based on clinical judgment and historical control studies. We then analyzed the characteristics of patients according to duration of treatment. RESULTS The overall response rate (ORR) for the <1-year group was 43%, the median PFS 4.6 months [95% confidence interval (95% CI) 3.8-6.4] with only 6% at 12 months, and the median OS was 15 months (11.7-20.3) and 40% at 18 months. For the ≥1-year group, the response rate and survival were strikingly different, ORR at 83%, median PFS 20.7 months (14.7-35.4), median OS not reached, and 91% at 18 months. CONCLUSION Pomalidomide and dexamethasone favored prolonged and safe exposure to treatment in 40% of heavily treated and end-stage RRMM, a paradigm shift in the natural history of RRMM characterized with a succession of shorter disease-free intervals and ultimately shorter survival. Although an optimization of pomalidomide-dexamethasone regimen is warranted in advanced RRMM, we claim that pomalidomide has proven once more to change the natural history of myeloma in this series, which should be confirmed in a larger study.
Collapse
Affiliation(s)
- G Fouquet
- Department of Blood Diseases, Hôpital Huriez, CHRU Lille, Lille
| | - B Pegourie
- Department of Hematology, Hôpital A.Michallon, CHU Grenoble, Grenoble
| | - M Macro
- Department of Hematology, Hôpital Côte de Nacre, CHU Caen, Caen
| | - M O Petillon
- Department of Blood Diseases, Hôpital Huriez, CHRU Lille, Lille
| | - L Karlin
- Department of Hematology, Centre Hospitalier Lyon-Sud, Lyon
| | - D Caillot
- Department of Hematology, CHU de Dijon, Dijon
| | - M Roussel
- Department of Hematology, CHU de Toulouse, Toulouse
| | - B Arnulf
- Department of Hematology, Hôpital Saint Louis, APHP, Paris
| | - C Mathiot
- Intergroupe Francophone du Myélome (IFM)
| | - G Marit
- Department of Hematology and Cell Therapy Service, CHU de Bordeaux, Pessac, France
| | - B Kolb
- Department of Hematology, Hôpital Robert Debré, CHU Reims, Reims
| | - A M Stoppa
- Department of Hematology, Institut Paoli Calmettes, Marseille
| | - S Brechiniac
- Department of Hematology, CHU Avicennes, APHP, Paris
| | - V Richez
- Department of Hematology, CHU Nice, Nice
| | - P Rodon
- Department of Hematology, CH de Périgueux, Périgueux
| | - A Banos
- Department of Hematology, CH de la Côte Basque, Bayonne
| | - M Wetterwald
- Department of Hematology, CH de Dunkerque, Dunkerque
| | - L Garderet
- Department of Hematology, CHU St-Antoine, Paris
| | - B Royer
- Department of Hematology, Hôpital Sud, CHU Amiens, Amiens
| | - C Hulin
- Department of Hematology, Hôpital de Nancy, Nancy
| | - L Benbouker
- Department of Hematology, Hôpital de Tours, Tours
| | - O Decaux
- Department of Hematology, CHU Rennes, Rennes
| | | | - J P Fermand
- Department of Hematology, Hôpital Saint Louis, APHP, Paris
| | - M Attal
- Department of Hematology, CHU de Toulouse, Toulouse
| | | | - P Moreau
- Department of Hematology, CHU Nantes, Nantes
| | - T Facon
- Department of Blood Diseases, Hôpital Huriez, CHRU Lille, Lille
| | - X Leleu
- Department of Hematology, CHU Poitiers, Poitiers
| | | |
Collapse
|
12
|
Metges J, Khobta N, Boschetti G, Karlin L, Toledano A, Aubron-olivier C, Fernet D, Fitoussi O. 1567 Overview of French routine clinical practice for the management of chemotherapy-induced anemia (CIA) with biosimilar epoetin alfa in 1298 patients with solid tumors: A national observational study (The OncoBOS study). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30656-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
13
|
Dimopoulos M, Cheung M, Roussel M, Liu T, Gamberi B, Kolb B, Derigs H, Eom H, Belhadj K, Lenain P, van der Jagt R, Rigaudeau S, Hall R, Jaccard A, Tosikyan A, Karlin L, Bensinger W, Schots R, Chen G, Marek J, Ervin-Haynes A, Facon T. Continuous Lenalidomide and Low-Dose Dexamethasone for the Treatment of Patients with Newly Diagnosed Multiple Myeloma and Renal Impairment in the First Trial. Clinical Lymphoma Myeloma and Leukemia 2015. [DOI: 10.1016/j.clml.2015.07.339] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
14
|
Fouquet G, Macro M, Decaux O, Fohrer C, Guidez S, Demarquette H, Le Grand C, Prodhomme C, Renaud L, Bories C, Herbaux C, Karlin L, Roussel M, Benboubker L, Hulin C, Arnulf B, Leleu X. [Pomalidomide for multiple myeloma]. Rev Med Interne 2015; 36:613-8. [PMID: 26257103 DOI: 10.1016/j.revmed.2015.04.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2014] [Revised: 03/08/2015] [Accepted: 04/22/2015] [Indexed: 11/30/2022]
Abstract
Once characterized by a very poor outcome, multiple myeloma (MM) now has a significantly prolonged survival, with major improvements allowed by the use of "novel agents": proteasome inhibitors (first-in-class bortezomib) and immunomodulatory compounds (IMiDs; first-in-class thalidomide and lenalidomide). However, the vast majority - if not all - of patients with MM ultimately end up being refractory to all existing drugs, including these efficient novel agents. There is a clear unmet medical need in this situation, which warrants the development of the next generation of proteasome inhibitors and IMiDs, as well as new drug classes. This review focuses on pomalidomide, the next generation IMiD, recently approved by the US FDA and the EMA for patients with relapsed or refractory MM who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on their last therapy.
Collapse
Affiliation(s)
- G Fouquet
- Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France
| | - M Macro
- Hématologie, hôpital Côte-de-Nacre, CHU, 1400 Caen, France
| | - O Decaux
- Médecine interne, hôpital Sud, CHRU, 35000 Rennes, France
| | - C Fohrer
- Hématologie, hôpital Hautepierre, CHU, 67000 Strasbourg, France
| | - S Guidez
- Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France
| | - H Demarquette
- Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France
| | - C Le Grand
- Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France
| | - C Prodhomme
- Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France
| | - L Renaud
- Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France
| | - C Bories
- Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France
| | - C Herbaux
- Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France
| | - L Karlin
- Service d'hématologie, hôpital Lyon-Sud, CHU, 69000 Lyon - Pierre-Bénite, France
| | - M Roussel
- Hématologie clinique, hôpital Purpan, CHU, 31000 Toulouse, France
| | - L Benboubker
- Onco-hématologie, hôpital Bretonneau, CHRU, 37000 Tours, France
| | - C Hulin
- Hématologie, hôpitaux de Brabois, CHU, 54000 Vandœuvre-lès-Nancy, France
| | - B Arnulf
- Hématologie-immunologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France
| | - X Leleu
- Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France.
| |
Collapse
|
15
|
Stathis A, Quesnel B, Amorim S, Thieblemont C, Zucca E, Raffoux E, Dombret H, Peng Y, Palumbo A, Vey N, Thomas X, Michallet M, Gomez-Roca C, Recher C, Karlin L, Yee K, Rezai K, Preudhomme C, Facon T, Herait P. 5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70726-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
16
|
Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G, Karlin L, Hulin C, Gentil C, Guilhot F, Garderet L, Lamy T, Brechignac S, Pegourie B, Jaubert J, Dib M, Stoppa AM, Sebban C, Fohrer C, Fontan J, Fruchart C, Macro M, Orsini-Piocelle F, Lepeu G, Sohn C, Corre J, Facon T, Moreau P, Attal M, Avet-Loiseau H. Erratum: Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia 2014. [DOI: 10.1038/leu.2013.352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
17
|
Li Y, Gold M, Karlin L. Proximal Junctional Kyphosis After Vertical Expandable Prosthetic Titanium Rib Insertion. Spine Deform 2013; 1:425-433. [PMID: 27927368 DOI: 10.1016/j.jspd.2013.07.013] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/06/2012] [Revised: 07/25/2013] [Accepted: 07/27/2013] [Indexed: 10/26/2022]
Abstract
STUDY DESIGN Retrospective review of patients who had undergone vertical expandable prosthetic titanium rib (VEPTR) treatment at a single institution. OBJECTIVES To evaluate whether clinically significant proximal junctional kyphosis (PJK) occurs after VEPTR insertion. SUMMARY OF BACKGROUND DATA PJK is a potential problem after posterior spinal instrumentation and fusion. PJK after VEPTR insertion has not been well-described. METHODS A total of 68 patients underwent VEPTR treatment between 1999 and 2009. Diagnosis, age at time of VEPTR insertion, location of VEPTR anchors, preoperative and postoperative scoliosis, T2-T12 kyphosis and PJK, time from VEPTR insertion to development of PJK, revision procedure for significant PJK, change in PJK after the revision procedure, and PJK at final follow-up were recorded. RESULTS Four patients developed PJK (6%). One patient had congenital scoliosis with rib fusions, 1 had scoliosis associated with a syndrome, and 2 had neuromuscular scoliosis. Mean follow-up was 5.7 years. Average T2-T12 kyphosis and PJK before VEPTR insertion were 77° and 14°, respectively. Mean T2-T12 kyphosis and PJK after VEPTR insertion were 63° and 33°, respectively. Average T2-T12 kyphosis and PJK before the recommended revision procedure for treatment of PJK were 89° and 53°, respectively. All patients developed PJK within the first year after VEPTR insertion. Two patients underwent revision to growing rods. One of these patients had preoperative halo-gravity traction. Mean PJK in these 2 patients improved from 39° to 18° after revision and remained stable at 19° at an average follow-up of 2.9 years. CONCLUSIONS PJK after VEPTR insertion can occur. Patients with preoperative thoracic hyperkyphosis may be at higher risk. PJK can develop within the first year of VEPTR treatment, and can become progressive and severe enough to require complex interventions. In this small case series, patients were revised to growing rods.
Collapse
Affiliation(s)
- Ying Li
- Department of Orthopaedic Surgery, C.S. Mott Children's Hospital, 1540 E. Hospital Drive, SPC 4241, Ann Arbor, MI 48109-4241, USA.
| | - Meryl Gold
- Department of Orthopaedic Surgery, Children's Hospital Boston, 300 Longwood Avenue, Boston, MA 02115, USA
| | - Lawrence Karlin
- Department of Orthopaedic Surgery, Children's Hospital Boston, 300 Longwood Avenue, Boston, MA 02115, USA
| |
Collapse
|
18
|
Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G, Karlin L, Hulin C, Gentil C, Guilhot F, Garderet L, Lamy T, Brechignac S, Pegourie B, Jaubert J, Dib M, Stoppa AM, Sebban C, Fohrer C, Fontan J, Fruchart C, Macro M, Orsini-Piocelle F, Lepeu G, Sohn C, Corre J, Facon T, Moreau P, Attal M, Avet-Loiseau H. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia 2013; 28:675-9. [PMID: 23892719 DOI: 10.1038/leu.2013.225] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2013] [Revised: 07/03/2013] [Accepted: 07/09/2013] [Indexed: 12/27/2022]
Abstract
Deletions of the 1p region appear as a pejorative prognostic factor in multiple myeloma patients (especially 1p22 and 1p32 deletions) but there is a lack of data on the real impact of 1p abnormalities on an important and homogeneous group of patients. To address this issue we studied by fluorescence in situ hybridization (FISH) the incidence and prognostic impact of 1p22 and 1p32 deletions in 1195 patients from the IFM (Institut Francophone du Myélome) cell collection. Chromosome 1p deletions were present in 23.3% of the patients (271): 15.1% (176) for 1p22 and 7.3% (85) for 1p32 regions. In univariate analyses, 1p22 and 1p32 appeared as negative prognostic factors for progression-free survival (PFS): 1p22: 19.8 months vs 33.6 months (P<0.001) and 1p32: 14.4 months vs 33.6 months (P<0.001); and overall survival (OS): 1p22: 44.2 months vs 96.8 months (P=0.002) and 1p32: 26.7 months vs 96.8 months (P<0.001). In multivariate analyses, 1p22 and 1p32 deletions still appear as independent negative prognostic factors for PFS and OS. In conclusion, our data show that 1p22 and 1p32 deletions are major negative prognostic factors for PFS and OS for patients with MM. We thus suggest that 1p32 deletion should be tested for all patients at diagnosis.
Collapse
Affiliation(s)
- B Hebraud
- Unité de Génomique du Myélome, University Hospital, CRCT, INSERM U 1037, Université Paul Sabatier, Toulouse, France
| | - X Leleu
- Service des Maladies du Sang, Hopital Claude Huriez, CHRU, Lille, France
| | | | - M Roussel
- Hématologie Clinique, Hôpital Purpan, Toulouse, France
| | - D Caillot
- Department of Hematology, University Hospital, Dijon, France
| | - G Marit
- Department of Hematology, University Hospital, Bordeaux, France
| | - L Karlin
- Department of Hematology, University Hospital, Lyon, France
| | - C Hulin
- Department of Hematology, University Hospital, Nancy, France
| | - C Gentil
- Service d'Epidémiologie, CHU Toulouse, Toulouse, France
| | - F Guilhot
- CIC Inserm 0802, Centre Hospitalier Universitaire, Poitiers, France
| | - L Garderet
- Department of Hematology, University Hospital, Paris, France
| | - T Lamy
- Department of Hematology, University Hospital, Rennes, France
| | - S Brechignac
- Department of Hematology, University Hospital, Bobigny, France
| | - B Pegourie
- Department of Hematology, University Hospital, Grenoble, France
| | - J Jaubert
- Department of Hematology, University Hospital, St-Etienne, France
| | - M Dib
- Department of Hematology, University Hospital, Angers, France
| | - A-M Stoppa
- Department of Hematology, Institut Paoli Calmette, Marseille, France
| | - C Sebban
- Department of Hematology, Centre Léon Bérard, Lyon, France
| | - C Fohrer
- Department of Hematology, University Hospital, Strasbourg, France
| | - J Fontan
- Department of Hematology, University Hospital, Besancon, France
| | - C Fruchart
- Department of Hematology, Centre Francois Baclesse, Caen, France
| | - M Macro
- Department of Hematology, University Hospital, Caen, France
| | | | - G Lepeu
- Department of Hematology, Departmental Hospital, Avignon, France
| | - C Sohn
- Department of Hematology, Departmental Hospital, Toulon, France
| | - J Corre
- Unité de Génomique du Myélome, University Hospital, CRCT, INSERM U 1037, Université Paul Sabatier, Toulouse, France
| | - T Facon
- Service des Maladies du Sang, Hopital Claude Huriez, CHRU, Lille, France
| | - P Moreau
- Department of Hematology, University Hospital, Nantes, France
| | - M Attal
- Hématologie Clinique, Hôpital Purpan, Toulouse, France
| | - H Avet-Loiseau
- Unité de Génomique du Myélome, University Hospital, CRCT, INSERM U 1037, Université Paul Sabatier, Toulouse, France
| |
Collapse
|
19
|
Lagarde J, Cret C, Karlin L, Ameri A. [Petrous plasmacytoma revealed by a painful peripheral facial palsy]. Rev Neurol (Paris) 2011; 167:526-9. [PMID: 21195441 DOI: 10.1016/j.neurol.2010.10.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2010] [Accepted: 10/13/2010] [Indexed: 11/26/2022]
Abstract
INTRODUCTION The classical hypothesis of Bell's palsy, tempting in cases of peripheral facial palsy of rapid onset, must nevertheless be evoked with caution particularly if an intense pain is present, which should lead to search for a tumor of the skull base, especially the petrous bone. CASE REPORT A 43-year-old man presented a peripheral facial palsy of rapidly progressive onset. A petrous bone tumor was diagnosed on the CT scan, which revealed an aspect of a glomic tumor or a metastatic lesion. The final histological diagnosis was plasmacytoma. DISCUSSION This type of tumor has been rarely reported in this location. The radiological features are not specific at all, underlying the importance of searching for some associated signs such as a monoclonal protein and performing a histological examination when the firm diagnosis of a systemic disease like multiple myeloma has not been possible.
Collapse
Affiliation(s)
- J Lagarde
- Service de Neurologie, Centre Hospitalier de Meaux, 6-8 rue Saint-Fiacre, 77104 Meaux cedex, France.
| | | | | | | |
Collapse
|
20
|
|
21
|
Karlin L, Arnulf B, Chevret S, Ades L, Robin M, De Latour RP, Malphettes M, Kabbara N, Asli B, Rocha V, Fermand JP, Socie G. Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy. Bone Marrow Transplant 2010; 46:250-6. [DOI: 10.1038/bmt.2010.90] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
22
|
Kocher MS, Kasser JR, Waters PM, Bae D, Snyder BD, Hresko MT, Hedequist D, Karlin L, Kim YJ, Murray MM, Millis MB, Emans JB, Dichtel L, Matheney T, Lee BM. Lateral entry compared with medial and lateral entry pin fixation for completely displaced supracondylar humeral fractures in children. A randomized clinical trial. J Bone Joint Surg Am 2007; 89:706-12. [PMID: 17403790 DOI: 10.2106/jbjs.f.00379] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
BACKGROUND Closed reduction and percutaneous pin fixation is the treatment of choice for completely displaced (type-III) extension supracondylar fractures of the humerus in children, although controversy persists regarding the optimal pin-fixation technique. The purpose of this study was to compare the efficacy of lateral entry pin fixation with that of medial and lateral entry pin fixation for the operative treatment of completely displaced extension supracondylar fractures of the humerus in children. METHODS This prospective, randomized clinical trial had sufficient power to detect a 10% difference in the rate of loss of reduction between the two groups. The techniques of lateral entry and medial and lateral entry pin fixation were standardized in terms of the pin location, the pin size, the incision and position of the elbow used for medial pin placement, and the postoperative course. The primary study end points were a major loss of reduction and iatrogenic ulnar nerve injury. Secondary study end points included radiographic measurements, clinical alignment, Flynn grade, elbow range of motion, function, and complications. RESULTS The lateral entry group (twenty-eight patients) and the medial and lateral entry group (twenty-four patients) were similar in terms of mean age, sex distribution, and preoperative displacement, comminution, and associated neurovascular status. No patient in either group had a major loss of reduction. There was no significant difference between the rates of mild loss of reduction, which occurred in six of the twenty-eight patients treated with lateral entry and one of the twenty-four treated with medial and lateral entry (p = 0.107). There were no cases of iatrogenic ulnar nerve injury in either group. There were also no significant differences (p > 0.05) between groups with respect to the Baumann angle, change in the Baumann angle, humerocapitellar angle, change in the humerocapitellar angle, Flynn grade, carrying angle, elbow flexion, elbow extension, total elbow range of motion, return to function, or complications. CONCLUSIONS With use of the specific techniques employed in this study, both lateral entry pin fixation and medial and lateral entry pin fixation are effective in the treatment of completely displaced (type-III) extension supracondylar fractures of the humerus in children. LEVEL OF EVIDENCE Therapeutic Level I. See Instructions to Authors for a complete description of levels of evidence.
Collapse
Affiliation(s)
- Mininder S Kocher
- Department of Orthopaedic Surgery, Children's Hospital Boston, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Karlin L, Darmon M, Thiéry G, Ciroldi M, de Miranda S, Lefebvre A, Schlemmer B, Azoulay É. Respiratory status deterioration during G-CSF-induced neutropenia recovery. Bone Marrow Transplant 2005; 36:245-50. [PMID: 15937498 PMCID: PMC7092208 DOI: 10.1038/sj.bmt.1705037] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Exacerbation of prior pulmonary involvement may occur during neutropenia recovery. Granulocyte colony-stimulating factor (G-CSF)-related pulmonary toxicity has been documented in cancer patients, and experimental models suggest a role for G-CSF in acute lung injury during neutropenia recovery. We reviewed 20 cases of noncardiac acute respiratory failure during G-CSF-induced neutropenia recovery. Half the patients had received hematopoietic stem cell transplants. All patients experienced pulmonary infiltrates during neutropenia followed by respiratory status deterioration coinciding with neutropenia recovery. Neutropenia duration was 10 (4–22) days, and time between respiratory symptoms and the first day with more than 1000 leukocytes/mm3 was 1 (−0.5 to 2) day. Of the 20 patients, 16 received invasive or noninvasive mechanical ventilation, including 14 patients with acute respiratory distress syndrome (ARDS). Five patients died, with refractory ARDS. In patients with pulmonary infiltrates during neutropenia, G-CSF-induced neutropenia recovery carries a risk of respiratory status deterioration with acute lung injury or ARDS. Clinicians must maintain a high index of suspicion for this diagnosis, which requires eliminating another cause of acute respiratory failure, G-CSF discontinuation and ICU transfer for early supportive management including diagnostic confirmation and noninvasive mechanical ventilation.
Collapse
Affiliation(s)
- L Karlin
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital and Paris 7 University, Assistance Publique, Hôpitaux de Paris, Paris France
| | - M Darmon
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital and Paris 7 University, Assistance Publique, Hôpitaux de Paris, Paris France
| | - G Thiéry
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital and Paris 7 University, Assistance Publique, Hôpitaux de Paris, Paris France
| | - M Ciroldi
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital and Paris 7 University, Assistance Publique, Hôpitaux de Paris, Paris France
| | - S de Miranda
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital and Paris 7 University, Assistance Publique, Hôpitaux de Paris, Paris France
| | - A Lefebvre
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital and Paris 7 University, Assistance Publique, Hôpitaux de Paris, Paris France
| | - B Schlemmer
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital and Paris 7 University, Assistance Publique, Hôpitaux de Paris, Paris France
| | - É Azoulay
- Medical Intensive Care Unit, Saint-Louis Teaching Hospital and Paris 7 University, Assistance Publique, Hôpitaux de Paris, Paris France
| |
Collapse
|
24
|
Abstract
This study was designed to determine the efficacy of waterproof cast-lining materials in children with short-arm, long-arm, and short-leg casts. Eligible patients had healing fractures 2 weeks after reduction, stable fractures requiring no reduction, or sprains. A total of 165 waterproof-lined casts were applied and 124 children and parents completed a survey (76.9%) upon cast removal. Results revealed 79% very satisfied, 21% satisfied, and 0% dissatisfied. There were 16 (12.9%) minor skin integrity issues. Waterproof casts in stable fractures and sprains allow acceptable immobilization with no significant associated unusual risk and allow children to resume their usual recreational water activities and hygiene regimen without risk of adverse results.
Collapse
|
25
|
Mukand J, Karlin L, Barrs K, Lublin P. Midodrine for the management of orthostatic hypotension in patients with spinal cord injury: A case report. Arch Phys Med Rehabil 2001; 82:694-6. [PMID: 11346851 DOI: 10.1053/apmr.2001.22350] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
A 21-year-old man sustained anterior displacement and a burst fracture of C7 in a motor vehicle crash. He underwent anterior corpectomy, decompression, fusion of C6-T1 vertebrae, and halo placement. The American Spinal Injury Association grade of his spinal cord injury (SCI) was C6 C tetraplegia. Severe orthostatic hypotension in the upright position complicated the patient's rehabilitation program. Midodrine was prescribed, and other medications with possible adverse effects were adjusted. Significant improvement after taking midodrine was reflected in the orthostatic vital signs and symptoms, as well as in FIM instrument scores. Staff noted improvements with therapy participation and functional status. The patient tolerated the midodrine well and had no significant side effects.
Collapse
Affiliation(s)
- J Mukand
- Southern New England Rehabilitation Center, Department of Orthopedics and Rehabilitation, Brown University, Providence, RI, USA
| | | | | | | |
Collapse
|
26
|
Mukand J, Karlin L, Biener-Bergman S. Rehabilitation and wellness after spinal cord injury. Med Health R I 2000; 83:79-82. [PMID: 10800351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/14/2023]
Affiliation(s)
- J Mukand
- Southern New England Rehabilitation Center, Providence, RI 02907, USA
| | | | | |
Collapse
|
27
|
Soliman DE, Maslow AD, Bokesch PM, Strafford M, Karlin L, Rhodes J, Marx GR. Transoesophageal echocardiography during scoliosis repair: comparison with CVP monitoring. Can J Anaesth 1998; 45:925-32. [PMID: 9836027 DOI: 10.1007/bf03012298] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Abstract
PURPOSE Accurate haemodynamic assessment during surgical repair of scoliosis is crucial to the care of the patient. The purpose of this study was to compare transoesophageal echocardiography (TEE) with central venous pressure monitoring in patients with spinal deformities requiring surgery in the prone position. METHODS Twelve paediatric patients undergoing corrective spinal surgery for scoliosis/kyphosis in the prone position were studied. Monitoring included TEE, intra-arterial and central venous pressure monitoring (CVP). Haemodynamic assessment was performed prior to and immediately after positioning the patient prone on the Relton-Hall table. Data consisted of mean arterial blood pressure (mBP), heart rate (HR), CVP, left ventricular end-systolic and end-diastolic diameters (LVESD and LVEDD respectively) and fractional shortening (FS). Right ventricular (RV) function and tricuspid regurgitation (TR) were assessed qualitatively. Analysis was performed using descriptive statistics, Student's t test, sign rank, and correlation analysis. RESULTS There was an increase in CVP (8.7 mmHg to 17.7 mmHg; P < .01), and decreases in LVEDD (37.1 mm to 33.2 mm; P < .05), and mean blood pressure (75.0 mmHg to 65.7 mmHg; P < .05) when patients were placed in the prone position. Fractional shortening, LVESD, and HR did not change from the supine to the prone position. Right ventricular systolic function and tricuspid regurgitation were unchanged. CONCLUSION These data indicate that the CVP is a misleading monitor of cardiac volume in patients with kyphosis/scoliosis in the prone position. This is consistent with previous studies. In this clinical situation, TEE may be a more useful monitoring tool to assess on-line ventricular size and function.
Collapse
Affiliation(s)
- D E Soliman
- Department of Anaesthesia, New England Medical Center, Boston, MA, USA
| | | | | | | | | | | | | |
Collapse
|
28
|
Abstract
Segmental spinal dysgenesis is characterized by focal agenesis or dysgenesis of the lumbar or thoracolumbar spine, with focal abnormality of the underlying spinal cord and nerve roots. Children are symptomatic at birth with lower limb deformities and neurological deficits that may be segmental. Myelography and computed tomography disclose hypoplastic or absent vertebrae and atrophic or absent neural elements adjacent to the bony deformity; the spinal column distal to the abnormality may be partially bifid, but is otherwise normal. Spinal ultrasonography was a helpful diagnostic adjunct in one patient. Surgery may be helpful in decompressing partially functioning spinal cord or nerve roots, but may exaggerate the tendency toward spinal instability. The embryology of this abnormality is not clear, but two children had other anomalies suggesting a spinal dysraphic syndrome, and its cause is probably related to a segmental maldevelopment of the neural tube.
Collapse
Affiliation(s)
- R M Scott
- Department of Neurosurgery, New England Medical Center, Boston, Massachusetts
| | | | | | | | | |
Collapse
|
29
|
Karlin L, Martz MJ, Brauth E, Mordkoff AM. Auditory evoked potentials, motor potentials and reaction time. Electroencephalogr Clin Neurophysiol 1971; 31:129-36. [PMID: 4104701 DOI: 10.1016/0013-4694(71)90182-9] [Citation(s) in RCA: 55] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
30
|
Jehn UW, Karlin L. Independent Action of Thymus and Bone Marrow Cells During the Secondary Response of Direct Plaque-Forming Cells. The Journal of Immunology 1971. [DOI: 10.4049/jimmunol.106.4.946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Abstract
Thymocytes and bone marrow cells from normal mice or from mice primed with SRBC were used to repopulate heavily irradiated mice. The recipients were challenged with SRBC and the PFC formed in their spleens were enumerated. The thymus-marrow synergism characteristic of unprimed cells was not found when primed cells were used in the restoring inoculum. Thymocytes and marrow cells from primed mice were each capable of restoring immunocompetence in the recipients, and in contrast with the corresponding cells from unprimed animals they appeared to react immunologically as independent units.
Collapse
Affiliation(s)
- Ulrich W. Jehn
- Clinical Immunology Service, New England Medical Center Hospitals , and the , Boston, Massachusetts 02111
- Department of Medicine, Tufts University School of Medicine , and the , Boston, Massachusetts 02111
| | - Lawrence Karlin
- Clinical Immunology Service, New England Medical Center Hospitals , and the , Boston, Massachusetts 02111
- Department of Medicine, Tufts University School of Medicine , and the , Boston, Massachusetts 02111
| |
Collapse
|
31
|
Jehn UW, Karlin L. Independent action of thymus and bone marrow cells during the secondary response of direct plaque-forming cells. J Immunol 1971; 106:946-50. [PMID: 4928748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
32
|
|
33
|
|
34
|
Abstract
The effects of changing the number of choices in the first response on “psychological refractoriness” were found to be partially consistent with intermittency theory but modifications may be needed to explain the results when the number of choices in the second response is increased.
Collapse
|
35
|
Merler E, Karlin L, Matsumoto S. The valency of human gamma-M immunoglobulin antibody. J Biol Chem 1968; 243:386-90. [PMID: 4966234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
|
36
|
|
37
|
|
38
|
|
39
|
|
40
|
Karlin L. An Improved Circuit for Connecting the Hunter Timer and Similar Timers in Sequence. The American Journal of Psychology 1954. [DOI: 10.2307/1418642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
41
|
|